Genetic Signatures Ltd (ASX: GSS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Genetic Signatures Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $210.98 million
P/E Ratio 125.00
Dividend Yield N/A
Shares Outstanding 143.04 million
Earnings per share 0.036
Dividend per share N/A
Year To Date Return -24.88%
Earnings Yield 0.80%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Genetic Signatures Ltd (ASX: GSS)
Latest News

GSS ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Genetic Signatures Ltd

Genetic Signatures Limited is a molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base™

GSS Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
19 Oct 2021 $1.50 $-0.01 -0.66% 29,099 $1.52 $1.52 $1.44
18 Oct 2021 $1.51 $0.09 6.34% 111,159 $1.42 $1.51 $1.39
15 Oct 2021 $1.42 $0.03 2.16% 14,132 $1.39 $1.42 $1.38
14 Oct 2021 $1.39 $-0.01 -0.71% 20,317 $1.42 $1.42 $1.38
13 Oct 2021 $1.40 $0.02 1.45% 17,914 $1.37 $1.40 $1.37
12 Oct 2021 $1.38 $-0.11 -7.38% 175,547 $1.44 $1.44 $1.36
11 Oct 2021 $1.49 $0.05 3.47% 45,245 $1.44 $1.49 $1.40
08 Oct 2021 $1.44 $0.07 5.09% 36,690 $1.40 $1.44 $1.38
07 Oct 2021 $1.38 $-0.02 -1.43% 31,779 $1.40 $1.40 $1.38
06 Oct 2021 $1.40 $0.02 1.46% 13,417 $1.39 $1.40 $1.38
05 Oct 2021 $1.37 $-0.06 -4.20% 107,650 $1.40 $1.40 $1.37
04 Oct 2021 $1.43 $0.03 2.14% 56,722 $1.40 $1.43 $1.39
01 Oct 2021 $1.40 $-0.05 -3.46% 48,220 $1.40 $1.44 $1.40
30 Sep 2021 $1.45 $-0.02 -1.36% 21,836 $1.44 $1.47 $1.43
29 Sep 2021 $1.47 $-0.02 -1.34% 55,897 $1.49 $1.49 $1.43
28 Sep 2021 $1.49 $0.00 0.00% 131,805 $1.49 $1.50 $1.44
27 Sep 2021 $1.49 $-0.02 -1.33% 113,079 $1.52 $1.52 $1.48
24 Sep 2021 $1.51 $-0.02 -1.32% 53,604 $1.53 $1.57 $1.50
23 Sep 2021 $1.52 $0.00 0.00% 70,545 $1.53 $1.57 $1.52
22 Sep 2021 $1.53 $-0.03 -1.93% 74,290 $1.60 $1.60 $1.52
21 Sep 2021 $1.56 $0.01 0.65% 131,048 $1.55 $1.65 $1.53

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
20 Nov 2020 John Melki Buy 250 $437,500
As advised by the company. Nature of change is not mentioned.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Dr Anthony (Tony) Radford Non-Executive Director Sep 2015
Dr Radford was a member of the CSIRO team that invented the QuantiFERON method for Cellular Immune based diagnostics. He later joined AMRAD in pharmaceutical research and was Head of Development in 2000 when he left to co-found the Cellestis Limited, which listed on the ASX in 2001. Dr Radford was CEO of Cellestis from founding until its acquisition by QIAGEN NV in 2011. He is Member of Risk Committee.
Dr Nicholas Samaras Non-Executive ChairmanNon-Executive Director Jan 2008
Dr Samaras has had over 30 years' business experience in the global Life Sciences industry and has industry experience. He has held a number of senior executive level positions in management, marketing, sales, and research and development. His roles have included appointments as Managing Director of Applied Biosystems Pty Ltd (now part of Thermo Fisher), and senior roles with Perkin Elmer and AMRAD Corporation (now part of CSL). Dr Samaras is an experienced executive, non-executive and Board Chairman, having served on the boards of several biotechnology companies including one that was ASX-listed. For the past 16 years Dr Samaras has worked on facilitating the international market expansion of a number of US biotechnology companies and developing commercial revenue channels outside of their traditional onshore market. He is Member of Risk Committee.
Mr Michael Anton Aicher Executive Director - US Operations May 2014
Mr Aicher has over 30 years of industry experience and was CEO and founder of National Genetics Institute (NGI) which was acquired by Laboratory Corporation of America, Inc. (LabCorp) in 2000. Prior to NGI, Mr Aicher served in a number of executive leadership roles at Central Diagnostics Laboratory. He currently serves as a director on boards of Alveo Technologies and Fabric Genomics.
Mr John Robert Melki Chief Executive OfficerManaging Director Apr 2014
Mr Melki has authored 20 peer-reviewed articles and is listed as an inventor on eight patent applications. Mr Melki worked in the sodium bisulphite conversion of DNA.
Dr Neil Gunn Non-Executive Director Apr 2021
Dr Gunn has over 30 years of medical device and diagnostics experience from managing operations in both Europe and the USA. He has knowledge of the diagnostic market, global product development, clinical, quality and regulatory processes, strategy development and commercial operations. Dr Gunn was until recently President of Roche Sequencing Solutions, a Business Unit of Roche Diagnostics. As head of Roche Sequencing Solutions (RSS) Dr Gunn has managed all aspects of the business. Prior to this he held the role of Vice President in Roche's Molecular Diagnostic business unit. During this twelve-year tenure, he was responsible for over 120 diagnostic product launches (Instruments, assays, Software) with a principle focus on IVD clinical markets.
Mr Peter L Manley Chief Financial OfficerCompany Secretary Mar 2019
-
Peter L Manley Chief Financial OfficerCompany Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Asia Union Investments My Ltd 37,500,000 26.29%
HSBC Custody Nominees 15,934,528 11.17%
Hsbc Custody Nominees (Australia) Limited 12,951,351 9.08%
UBS Nominees My Ltd 6,942,586 4.87%
National Nominees Limited 5,968,614 4.18%
Citicorp Nominees Pty Limited 5,598,723 3.92%
J P Morgan Nominees Australia Pty Limited 4,171,672 2.92%
BNP Paribas Noms Pp/ Ltd <Drp> 2,256,965 1.58%
Brispot Nominees Pty Ltd <House Head Nominee A/C> 2,113,799 1.48%
Capital Concerns Ptv Limited <Logue Family Super Fund A/C> 2,110,000 1.48%
Dr Nick Samaras And Associated Entities 2,024,016 1.42%
Graham Consolidated Pty Ltd 1,654,073 1.16%
Mr Phillip Isaacs And Associated Entities 1,612,143 1.13%
Mr John Robert Melki 1,096,000 0.77%
S Loader Pty Ltd <S Loader Superfund A/C> 1,042,880 0.73%
Graham Investments My Ltd <Graham Staff Super Fund A/C> 886,368 0.62%
CS Fourth Nominees Pty Limited <Hsbc Cust Nom Au Ltd 11 A/C> 802,578 0.56%
Idollink Pty Ltd <Mckeith Super Fund A/C> 796,927 0.56%
Quickinvest Pty Ltd <Quickinvest Staff S/F A/C> 756,349 0.53%
BNP Paribas Nominees Pty Ltd <Agency Lending Orp A/C> 736,164 0.52%

Profile

since

Note